PD-L1 Testing in Non-small Cell Lung Cancer: Past, Present, and Future

키워드

참고문헌 (57)

1. Borghaei H, "Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer", N Engl J Med, 373, pp.1627~1639 (2015)
2. Brahmer J, "Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer", N Engl J Med, 373, pp.123~135 (2015)
3. Reck M, "Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer", N Engl J Med, 375, pp.1823~1833 (2016)
4. Herbst RS, "Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer(KEYNOTE-010) : a randomised controlled trial", Lancet, 387, pp.1540~1550 (2016)
5. Fehrenbacher L, "Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer(POPLAR) : a multicentre, open-label, phase 2 randomised controlled trial", Lancet, 387, pp.1837~1846 (2016)
6. Rittmeyer A, "Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer(OAK) : a phase 3, open-label, multicentre randomised controlled trial", Lancet, 389, pp.255~265 (2017)
7. Gulley JL, "Avelumab for patients with previously treated metastatic or recurrent non-small-cell lung cancer(JAVELIN Solid Tumor) : dose-expansion cohort of a multicentre, open-label, phase 1b trial", Lancet Oncol, 18, pp.599~610 (2017)
8. Garassino MC, "Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer(ATLANTIC) : an open-label, single-arm, phase 2 study", Lancet Oncol, 19, pp.521~536 (2018)
9. "Non-small cell lung cancer. Version 3.2018" (2018)[URL]
10. Dunn GP, "Cancer immunoediting : from immunosurveillance to tumor escape", Nat Immunol, 3, pp.991~998 (2002)
11. Pardoll DM, "The blockade of immune checkpoints in cancer immunotherapy", Nat Rev Cancer, 12, pp.252~264 (2012)
12. Schreiber RD, "Cancer immunoediting : integrating immunity's roles in cancer suppression and promotion", Science, 331, pp.1565~1570 (2011)
13. Brahmer JR, "Safety and activity of anti-PD-L1 antibody in patients with advanced cancer", N Engl J Med, 366, pp.2455~2465 (2012)
14. Hirsch FR, "PD-L1 Immunohistochemistry assays for lung cancer : results from phase 1 of the Blueprint PD-L1 IHC assay comparison project", J Thorac Oncol, 12, pp.208~222 (2017)
15. Scheel AH, "Harmonized PD-L1 immunohistochemistry for pulmonary squamous-cell and adenocarcinomas", Mod Pathol, 29, pp.1165~1172 (2016)
16. Rimm DL, "A prospective, multi-institutional, pathologist-based assessment of 4 immunohistochemistry assays for PD-L1 expression in non-small cell lung cancer", JAMA Oncol, 3, pp.1051~1058 (2017)
17. Adam J, "Multicenter harmonization study for PD-L1 IHC testing in non-small-cell lung cancer", Ann Oncol, 29, pp.953~958 (2018)
18. Ratcliffe MJ, "Agreement between programmed cell death ligand-1 diagnostic assays across multiple protein expression cutoffs in non-small cell lung cancer", Clin Cancer Res, 23, pp.3585~3591 (2017)
19. Maher A. Sughayer, "Comparison of 22C3 PharmDx and SP263 Assays to Test PD-L1 Expression in NSCLC", Applied Immunohistochemistry & Molecular Morphology, 27(9), pp.663~666 (2019), Ovid Technologies (Wolters Kluwer Health)[DOI]
20. Tsao MS, "PD-L1 immunohistochemistry comparability study in real-life clinical samples : results of Blueprint Phase 2 Project", J Thorac Oncol, 13, pp.1302~1311 (2018)
21. Fujimoto D, "Predictive performance of four programmed cell death ligand 1 assay systems on nivolumab response in previously treated patients with non-small cell lung cancer", J Thorac Oncol, 13, pp.377~386 (2018)
22. Marchetti A, "Multicenter comparison of 22C3 PharmDx(Agilent)and SP263(Ventana)assays to test PD-L1expression for NSCLC patients to be treated with immune checkpoint inhibitors", J Thorac Oncol, 12, pp.1654~1663 (2017)
23. "VENTANA PD-L1 (SP263) Assay (CE IVD)" (2019)[URL]
24. Munari E, "PD-L1 assays 22C3 and SP263are not interchangeable in non-small cell lung cancer when considering clinically relevant cutoffs : an interclone evaluation by differently trained pathologists", Am J Surg Pathol, 42, pp.1384~1389 (2018)
25. Hendry S, "Comparison of four PD-L1immunohistochemical assays in lung cancer", J Thorac Oncol, 13, pp.367~376 (2018)
26. Tsao MS, "IASLC atlas of PD-L1 immunohistochemistry testing in lung cancer" (2017), International Association for the Study of Lung Cancer
27. Herbst RS, "Use of archival versus newly collected tumor samples for assessing PD-L1 expression and overall survival : an updated analysis of KEYNOTE-010 trial", Ann Oncol, 30, pp.281~289 (2019)
28. Omori S, "Changes in programmed death ligand 1 expression in non-small cell lung cancer patients who received anticancer treatments", Int J Clin Oncol, 23, pp.1052~1059 (2018)
29. Sheng J, "Expression of programmed death ligand-1 on tumor cells varies pre and post chemotherapy in nonsmall cell lung cancer", Sci Rep, 6, pp.20090~ (2016)
30. 신정훈, "Effect of Platinum-Based Chemotherapy on PD-L1 Expression on Tumor Cells in Non-small Cell Lung Cancer", Cancer Research and Treatment, 51(3), pp.1086~1097 (2019), 대한암학회
31. Azuma K, "Association of PD-L1 overexpression with activating EGFR mutations in surgically resected nonsmall-cell lung cancer", Ann Oncol, 25, pp.1935~1940 (2014)
32. Han JJ, "Change in PD-L1 expression after acquiring resistance to gefitinib in EGFR-mutant non-small-cell lung cancer", Clin Lung Cancer, 17, pp.263.e2~270.e2 (2016)
33. Ilie M, "Comparative study of the PDL1status between surgically resected specimens and matched biopsies of NSCLC patients reveal major discordances : a potential issue for anti-PD-L1 therapeutic strategies", Ann Oncol, 27, pp.147~153 (2016)
34. Gniadek TJ, "Heterogeneous expression of PD-L1 in pulmonary squamous cell carcinoma and adenocarcinoma : implications for assessment by small biopsy", Mod Pathol, 30, pp.530~538 (2017)
35. Kim H, "PD-L1 immunohistochemical assays for assessment of therapeutic strategies involving immune checkpoint inhibitors in non-small cell lung cancer : a comparative study", Oncotarget, 8, pp.98524~98532 (2017)
36. Mansfield AS, "Heterogeneity of programmed cell death ligand 1 expression in multifocal lung cancer", Clin Cancer Res, 22, pp.2177~2182 (2016)
37. Kim S, "Comparative analysis of PD-L1 expression between primary and metastatic pulmonary adenocarcinomas", Eur J Cancer, 75, pp.141~149 (2017)
38. Niemeijer AN, "Whole body PD-1and PD-L1 positron emission tomography in patients with nonsmall-cell lung cancer", Nat Commun, 9, pp.4664~ (2018)
39. Ilié M, "Detection of PD-L1 in circulating tumor cells and white blood cells from patients with advanced non-small-cell lung cancer", Ann Oncol, 29, pp.193~199 (2018)
40. Guibert N, "PD-L1 expression in circulating tumor cells of advanced non-small cell lung cancer patients treated with nivolumab", Lung Cancer, 120, pp.108~112 (2018)
41. Rebelatto MC, "Development of a programmed cell death ligand-1 immunohistochemical assay validated for analysis of non-small cell lung cancer and head and neck squamous cell carcinoma", Diagn Pathol, 11, pp.95~ (2016)
42. Skov BG, "Paired comparison of PD-L1 expression on cytologic and histologic specimens from malignancies in the lung assessed with PD-L1 IHC 28-8pharmDx and PD-L1 IHC 22C3pharmDx", Appl Immunohistochem Mol Morphol, 25, pp.453~459 (2017)
43. Heymann JJ, "PD-L1 expression in non-small cell lung carcinoma : comparison among cytology, small biopsy, and surgical resection specimens", Cancer Cytopathol, 125, pp.896~907 (2017)
44. Wang H, "Cytology cell blocks are suitable for immunohistochemical testing for PD-L1 in lung cancer", Ann Oncol, 29, pp.1417~1422 (2018)
45. Rizvi NA, "Cancer immunology : mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer", Science, 348, pp.124~128 (2015)
46. Hellmann MD, "Nivolumab plus ipilimumab in lung cancer with a high tumor mutational burden", N Engl J Med, 378, pp.2093~2104 (2018)
47. Mazzaschi G, "Low PD-1 expression in cytotoxic CD8(+)tumor-infiltrating lymphocytes confers an immuneprivileged tissue microenvironment in NSCLC with a prognostic and predictive value", Clin Cancer Res, 24, pp.407~419 (2018)
48. Kim H, "Increased CD3+ T cells with a low FOXP3+", CD8+ T cell ratio can predict anti-PD-1 therapeutic response in non-small cell lung cancer patients, 2019, pp.32, 367~375
49. Postow MA, "Peripheral T cell receptor diversity is associated with clinical outcomes following ipilimumab treatment in metastatic melanoma", J Immunother Cancer, 3, pp.23~ (2015)
50. Weber JS, "A serum protein signature associated with outcome after anti-PD-1 therapy in metastatic melanoma", Cancer Immunol Res, 6, pp.79~86 (2018)
51. Sivan A, "Commensal Bifidobacterium promotes antitumor immunity and facilitates anti-PD-L1 efficacy", Science, 350, pp.1084~1089 (2015)
52. Snyder A, "Genetic basis for clinical response to CTLA-4 blockade in melanoma", N Engl J Med, 371, pp.2189~2199 (2014)
53. Hellmann MD, "Tumor mutational burden and efficacy of nivolumab monotherapy and in combination with ipilimumab in small-cell lung cancer", Cancer Cell, 33, pp.853.e4~861.e4 (2018)
54. Le DT, "PD-1 blockade in tumors with mismatch-repair deficiency", N Engl J Med, 372, pp.2509~2520 (2015)
55. Carbone DP, "First-line nivolumab in stage IV or recurrent non-small-cell lung cancer", N Engl J Med, 376, pp.2415~2426 (2017)
56. Rizvi H, "Molecular determinants of response to anti-programmed cell death(PD)-1 and anti-programmed death-ligand 1(PD-L1)blockade in patients with non-small-cell lung cancer profiled with targeted next-generation sequencing", J Clin Oncol, 36, pp.633~641 (2018)
57. Deans ZC, "Integration of next-generation sequencing in clinical diagnostic molecular pathology laboratories for analysis of solid tumours; an expert opinion on behalf of IQN Path ASBL", Virchows Arch, 470, pp.5~20 (2017)

관련 논문AI추천